On October, 30 IPHARMA received the Ministry of Health permission to conduct Phase I trial of Hondrolux®
Protocol № ОА-CLX-01 “Double-blind, randomized, placebo-controlled study to access safety and tolerability of single and following multiple escalating doses of the Khondrolux® study drug after a single and subsequent multiple intramuscular injection in healthy volunteers”.
The purpose of the clinical trial is to evaluate the safety and tolerability of the Khondrolux® with a single and subsequent multiple dose in healthy volunteers, including assessment of drug tolerance based on the frequency of local reactions.
Therapeutic area: rheumatology.
The Khondrolux is developed by SEA Peptides LLC for treatment and prevention of degenerative-dystrophic diseases of the joints and spine.